Navigation Links
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
Date:6/25/2008

- Once-daily dosing with enteric-coated tablet produced robust antiviral

activity - - RDEA806 was well tolerated during one week of dosing in HIV patients -

SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced additional positive results from its completed Phase 2a proof-of-concept monotherapy study of RDEA806, its novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in patients with human immunodeficiency virus (HIV).

These additional results demonstrated that once-daily dosing with the enteric-coated tablet formulation of RDEA806 resulted in significant reductions in plasma viral load that were consistent with results previously presented with twice-daily dosing of the capsule formulation in the same study. All dosing regimens tested in the study were well tolerated. Ardea's lead investigator plans to present the full data from this study at a medical conference later this year.

"RDEA806's robust antiviral potency, combined with its excellent tolerability profile in over 130 healthy volunteers and HIV-infected patients treated in clinical studies to-date, make RDEA806 a promising candidate for further investigation as a first-line agent for the treatment of HIV," said Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, and a lead investigator in the completed Phase 2a trial and planned Phase 2b study.

Phase 2a Clinical Trial Design & Top-line Results

The Phase 2a randomized, double-blind, placebo-controlled trial evaluated the antiviral activity, pharmacokinetics, safety and tolerability of once- and twice-daily oral dosing regimens of RDEA806 versus placebo in 48 HIV-pos
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
(Date:1/14/2014)... a manufacturer of ergonomically designed laboratory equipment for research, ... Japan to sell and service the Hitachi brand ... utilize its network of sales professionals throughout the United ... assistance in application use, product benefits and features, options and accessories, ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a privately ... for Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of January 15, ... at New York Medical College. Oligomerix, which ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Eisai Corporation of North America today announced that the ... review the company,s supplemental new drug application (sNDA) for ... injection) to treat patients with myelodysplastic syndromes (MDS). ... diseases that limit the production of functional blood cells. ...
... Amgen (Nasdaq: AMGN ) today announced that ... Zometa(R) (zoledronic acid) in the treatment of bone metastases ... primary and secondary endpoints and demonstrated superior efficacy compared ... the time to the first on-study Skeletal Related Events ...
Cached Medicine Technology:FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS) 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:4/23/2014)... a country as wealthy as the United States, it may ... not have access to adequate food due to lack of ... , Recent research at the University of Illinois using data ... that the seniors who are dealing with hunger are also ... 8.35 percent of Americans over age 60 faced the threat ...
(Date:4/23/2014)... PROVIDENCE, R.I. Parents and physicians concerned about an ... medical marijuana can breathe a sigh of relief. According ... compared 20 years worth of data from states with ... not lead to increased use among adolescents. The study ... Journal of Adolescent Health . , "Any ...
(Date:4/23/2014)... depletion of self-control, according to research published in ... Psychological Science. , Self-control can be difficult sticking ... a boring textbook are hard things to do. Considerable ... self-control for a long period seems to "deplete" our ... "It is as if self-control is a limited resource ...
(Date:4/22/2014)... a popular high school sport in the United States ... by researchers in the Center for Injury Research and ... compare and describe the occurrence and distribution patterns of ... school athletic training setting among adolescents and teens. , ... Athletic Training , examined data relating to adolescents 13-19 ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
Breaking Medicine News(10 mins):Health News:More Americans in their golden years are going hungry 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:ADHD drug may help preserve our self-control resources 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... Pa., June 1 Practice-Reps, LLC ( http://www.practice-reps.com ) ... to specialty medical practices along the East Coast. The ... a 16-year veteran of the practice marketing industry, to ... experienced marketing support on a part-time basis. , ...
... SAN FRANCISCO, Calif., June 1 Rigel Pharmaceuticals, Inc. ... oral Syk inhibitor, R788, is being evaluated in a ... the National Cancer Institute (NCI), part of the U.S. ... trial will include patients with advanced colorectal, thyroid, non-small ...
... , Collaboration Delivers Cost and Quality Benefits for Widespread ... June 1 SAFC(R) ( www.safcglobal.com ), a member ... and Cherokee Pharmaceuticals(TM) ( www.cherokee-pharma.com ... business, today announced an exclusive strategic partnership that encompasses ...
... , New Product Names for Recently Introduced MicroRNA-based Diagnostics ... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic ... platform yesterday at the American Society of Clinical Oncology ... a presentation entitled "Profiling of Receptor Tyrosine Kinases (RTK) ...
... the mouth and periodontists to ask questions about heart health ... leading killer of men and women in the United States, ... each day. Periodontal disease, a chronic inflammatory disease that destroys ... 75 percent of Americans and is the major cause of ...
... program aimed at reducing criminal behavior in juvenile justice teens ... reducing the teens, rate of pregnancy, according to a new ... in the Department of Psychology at Oregon State University, and ... Learning Center, conducted the research, which will be published in ...
Cached Medicine News:Health News:Practice-Reps Brings Sales and Marketing to the Business of Medical Practice Management 2Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 2Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 3Health News:SAFC(R) & Cherokee Pharmaceuticals(TM) Pool Expertise and Resources With Strategic Partnership For U.S. Market 2Health News:SAFC(R) & Cherokee Pharmaceuticals(TM) Pool Expertise and Resources With Strategic Partnership For U.S. Market 3Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 2Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 3Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 2Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 3Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 4Health News:Intervention reduces delinquent teenage pregancy rates 2Health News:Intervention reduces delinquent teenage pregancy rates 3
Three-spring evacuator kits with silicone drains, 10 in. hole pattern, trocar and Y-connector tubing...
Reliavac® 400cc kits with silicone round drain with 10 in. hole pattern, trocar, and Y-connector tubing...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used in the peritoneal cavity to remove large volumes of thick exudate....
Medicine Products: